Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gregory Roberts

Showing results (71-80 of 73) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 73 results.
Cancer Research|February 12, 2005
Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451W Gregory Roberts, Pamela M Whalen, Erik Soderstrom, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 2007
Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosisLeonard Buckbinder, David T Crawford, Hong Qi, et al.
Bioorganic & Medicinal Chemistry Letters|October 28, 2008
Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formationDaniel P Walker, F Christopher Bi, Amit S Kalgutkar, et al.
Pageof 8

Showing results (71-80 of 73) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 73 results.
Cancer Research|February 12, 2005
Antiangiogenic and antitumor activity of a selective PDGFR tyrosine kinase inhibitor, CP-673,451W Gregory Roberts, Pamela M Whalen, Erik Soderstrom, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 2007
Proline-rich tyrosine kinase 2 regulates osteoprogenitor cells and bone formation, and offers an anabolic treatment approach for osteoporosisLeonard Buckbinder, David T Crawford, Hong Qi, et al.
Bioorganic & Medicinal Chemistry Letters|October 28, 2008
Trifluoromethylpyrimidine-based inhibitors of proline-rich tyrosine kinase 2 (PYK2): structure-activity relationships and strategies for the elimination of reactive metabolite formationDaniel P Walker, F Christopher Bi, Amit S Kalgutkar, et al.
Pageof 8